Von Willebrand Disease

Von Willebrand disease (VWD) is a bleeding disorder. It affects your blood's ability to clot. If your blood doesn't clot, you can have heavy, hard-to-stop bleeding after an injury. The bleeding can damage your internal organs or even cause death, although this is rare.

In VWD, you either have low levels of a certain protein in your blood, or the protein doesn't work the way it should. The protein is called von Willebrand factor, and it helps the blood clot.

What is Von Willebrand Disease?

Von Willebrand disease is the most common inherited bleeding disorder that affects approximately 1% of the population, although not everyone is symptomatic. The disease can also be acquired later in life as a result of other health conditions.

Von Willebrand Disease Diagnosis

Von Willebrand Disease Pathophysiology

Von Willebrand Disease Symptoms

Von Willebrand Disease Types

Latest Von Willebrand Disease News and Research

COVID-19 complications may be associated with von Willebrand factor in the blood

Anna Aksenova, a senior research associate at the Laboratory of Amyloid Biology at St Petersburg University, has advanced a hypothesis that the severe course of COVID-19 may be associated with von Willebrand factor.

6 Jul 2020

Scientists find potential new way to improve treatment for Von Willebrand Disease

Scientists have found a potential new way to promote blood clotting that could be used to help develop treatments for Von Willebrand Disease, the most common genetic bleeding disorder.

12 Jun 2020

New evidence-based clinical practice guideline for nosebleed published

The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery.

7 Jan 2020

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

New drug approved by FDA for treatment of von Willebrand disease

"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.

22 Dec 2015

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

8 Dec 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

Engineered protein shown effective in patients with severe von Willebrand disease

The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial.

4 Aug 2015

CSL Behring awarded NHF's 2015 Corporate Leadership Award

The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.

24 May 2015

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.

7 May 2015

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

From Baxter International Inc. 16 Apr 2015

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A.

From Novo Nordisk 26 Mar 2015

CSL Behring donates protein therapies to World Federation of Hemophilia

In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced today that it is donating 2 million international units (IUs) of protein therapies to the World Federation of Hemophilia.

28 Feb 2015

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment.

From Novo Nordisk 7 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.

8 Oct 2014

School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

School nurses reach 98 percent of the 50,000,000 students in U.S. public schools, grades k-12, and are uniquely positioned to facilitate the early diagnosis of serious medical conditions such as primary immunodeficiency (PI).

28 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Von Willebrand Disease

Overview

Von Willebrand Disease Diagnosis

Von Willebrand Disease Pathophysiology

Von Willebrand Disease Symptoms

Feature Articles

Von Willebrand Disease Types

Latest Von Willebrand Disease News and Research

COVID-19 complications may be associated with von Willebrand factor in the blood

Scientists find potential new way to improve treatment for Von Willebrand Disease

New evidence-based clinical practice guideline for nosebleed published

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

New drug approved by FDA for treatment of von Willebrand disease

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

Engineered protein shown effective in patients with severe von Willebrand disease

CSL Behring awarded NHF's 2015 Corporate Leadership Award

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

CSL Behring donates protein therapies to World Federation of Hemophilia

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

School nurses reach 98% of students in U.S. public schools to diagnose primary immunodeficiency

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Eliminating the Cold Chain with COVID-19 Molecular Transport Media

Fecal transplants, the secret to eternal youth

Why do we need sleep?

Von Willebrand Disease

Overview

Feature Articles

Von Willebrand Disease Types

Latest Von Willebrand Disease News and Research

Newsletters you may be interested in